Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
The current AMLX market cap is 358.51M. The company's latest EPS is USD 0.7188 and P/E is 7.32.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 98.22M | 102.69M | 108.45M | 88.64M | -1.02M |
| Operating Income | 20.2M | 18.72M | 1.93M | -11.67M | -68.88M |
| Net Income | 22.07M | 20.89M | 4.73M | -118.79M | -72.7M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.43M | 1.43M | 285k | 22.23M | 380.79M |
| Operating Income | -13.55M | -13.55M | -82.69M | -201.34M | 38.8M |
| Net Income | -13.72M | -13.72M | -87.93M | -198.38M | 49.27M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 453.59M | 466.58M | 517.45M | 417.46M | 332.16M |
| Total Liabilities | 67.22M | 48.18M | 84.02M | 93.02M | 70.85M |
| Total Equity | 386.37M | 418.4M | 433.43M | 324.44M | 261.31M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 3.22M | 14.1M | 105.61M | 391.45M | 517.45M |
| Total Liabilities | 20.9M | 8.77M | 17.43M | 50.85M | 84.02M |
| Total Equity | -25.36M | -66.73M | -151.17M | 340.61M | 433.43M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 3.54M | -1.63M | 11.92M | -489k | -67.07M |
| Investing | 179.22M | 71.13M | 92.05M | 819k | -28.14M |
| Financing | 2.42M | 3.31M | 3.54M | 131k | 158k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -10.69M | -10.69M | -74.8M | -179.87M | 11.92M |
| Investing | N/A | N/A | -46.41M | -238.99M | 92.05M |
| Financing | 668k | 668k | 158.51M | 431.79M | 3.54M |
| Market Cap | 358.51M |
| Price to Earnings Ratio | 7.32 |
| Price to Sales Ratio | 0.95 |
| Price to Cash Ratio | 2.12 |
| Price to Book Ratio | 0.83 |
| Dividend Yield | - |
| Shares Outstanding | 68.55M |
| Average Volume (1 week) | 1.87M |
| Average Volume (1 Month) | 1.69M |
| 52 Week Change | -58.75% |
| 52 Week High | 19.9488 |
| 52 Week Low | 1.575 |
| Spread (Intraday) | 0.07 (1.33%) |
| Company Name | Amylyx Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.amylyx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
